natgillin/translations-raw huggingface dataset:
TITAN is a randomised, controlled, open-label Phase III trial comparing darunavir co-administered with ritonavir (600/100 mg twice daily) versus lopinavir/ritonavir (400/100 mg twice daily) in ARTexperienced, lopinavir naïve HIV-1 infected adult patients.
TITAN je randomizirano kontrolirano kliničko ispitivanje otvorenog tipa, faze III pri čemu je uspoređivan darunavir primijenjen istodobno s ritonavirom (600/100 mg dvaput na dan) naspram lopinavira/ritonavira (400/100 mg dvaput na dan) u odraslih bolesnika inficiranih HIV-1 prethodno liječenih ART-om, ali neliječenih lopinavirom.
Darunavir co-administered with cobicistat should not be used in combination with another antiretroviral agent that requires pharmacoenhancement by means of co-administration with an inhibitor of CYP3A4 (see section 4.5).
Darunavir istodobno primijenjen s kobicistatom ne smije se uzimati u kombinaciji s drugim antiretrovirusnim lijekovima koji zahtijevaju farmakokinetičko pojačanje u smislu istodobne primjene s inhibitorom CYP3A4 (vidjeti dio 4.5).
Darunavir Krkamust be taken in combination with a low dose of ritonavir and other anti-HIV medicines.
Darunavir Krka se mora uzimati u kombinaciji s niskom dozom ritonavira i drugim lijekovima protiv HIV-a.
No adjustment of methadone dosage is required when initiating coadministration with boosted darunavir.
Prilagodba doziranja metadona nije potrebna kada se započinje istodobna primjena s pojačanim darunavirom.
It is recommended that the international normalised ratio (INR) be monitored when warfarin is combined with boosted darunavir.
Preporučuje se praćenje protrombinskog vremena (INR, od engl. international normalised ratio) kada se varfarin primjenjuje u kombinaciji s pojačanim darunavirom.
A dose reduction of the co-administered drug may be needed in these cases.
U tim slučajevima može biti potrebno smanjiti dozu istodobno primijenjenog lijeka.
Ethinylestradiol Norethindrone 35 μg/1 mg once daily drospirenone AUC ↑ 58% drospirenone Cmin ND drospirenone Cmax ↑ 15%
35 μg/1 mg jedanput na dan drospirenon AUC ↑ 58% drospirenon Cmin NO drospirenon Cmax ↑ 15%
Concomitant administration of boosted darunavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Istodobna primjena pojačanog darunavira i kvetiapina je kontraindicirana jer može povisiti toksičnost povezanu s kvetiapinom.
Efavirenz in combination with boosted darunavir once daily may result in sub-optimal darunavir Cmin.
Efavirenz u kombinaciji s pojačanim darunavirom jedanput na dan može rezultirati suboptimalnom vrijednošću Cmin darunavira.
If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using darunavir used in combination with cobicistat or low dose ritonavir, interruption or discontinuation of treatment should be considered promptly.
Ako postoje dokazi o novoj ili pogoršanju disfunkcije jetre (uključujući klinički značajno povišenje enzima jetre i/ili simptomi poput umora, anoreksije, mučnine, žutice, tamne mokraće, osjetljivosti jetre, hepatomegalije) u bolesnika koji uzimaju darunavir koji se uzima u kombinaciji s kobicistatom ili niskom dozom ritonavira, mora se odmah razmotriti privremeni ili trajni prekid liječenja.
Perphenazine Risperidone Thioridazine
Perfenazin Risperidon Tioridazin
The pharmacokinetic properties of darunavir, co-administered with cobicistat or ritonavir, have been evaluated in healthy adult volunteers and in HIV-1 infected patients.
Farmakokinetička svojstva darunavira primjenjenog istodobno s kobicistatom ili ritonavirom, ispitivana su u zdravih odraslih dobrovoljaca i u bolesnika inficiranih s HIV-1.
If parenteral midazolam is co-administered with boosted darunavir it may cause a large increase in the concentration of this benzodiazepine.
Ako se parenteralni midazolam istodobno primjenjuje s pojačanim darunavirom to može izazvati velik porast koncentracija ovog benzodiazepina.
Take Darunavir Krkawith food.
- Lijek Darunavir Krka uzimajte s hranom.
A dose decrease may be needed for these drugs when co-administered with boosted darunavir.
Može biti potrebno smanjenje doze za te lijekove kada se primjenjuju istodobno s pojačanim darunavirom.
Other strengths of Darunavir Krka are available.
Dostupne su druge jačine lijeka Darunavir Krka.
Although the effect on CYP2C8 has only been studied in vitro, co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP2C8 (such as paclitaxel, rosiglitazone, repaglinide) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.
Iako je učinak na CYP2C8 bio ispitivan samo in vitro, istodobna primjena darunavira i ritonavira i drugih lijekova koji se primarno metaboliziraju putem CYP2C8 (poput paklitaksela, rosiglitazona, repaglinida) može rezultirati smanjenom sistemskom izloženosti tim lijekovima, što može smanjiti ili skratiti njihov terapijski učinak.
Darunavir should not be used in paediatric patients below 3 years of age or less than 15 kg body weight (see sections 4.4 and 5.3).
Darunavir se ne smije primjenjivati u pedijatrijskih bolesnika mlađih od 3 godine ili s manje od 15 kg tjelesne težine (vidjeti dijelove 4.4 i 5.3).
Darunavir contains a sulphonamide moiety.
Darunavir sadrži sulfonamidnu funkcionalnu skupinu.
Boceprevir 800 mg three times daily boceprevir AUC ↓ 32% boceprevir Cmin ↓ 35% boceprevir Cmax ↓ 25% darunavir AUC ↓ 44% darunavir Cmin ↓ 59% darunavir Cmax ↓ 36%
Boceprevir 800 mg triput na dan boceprevir AUC ↓ 32% boceprevir Cmin ↓ 35% boceprevir Cmax ↓ 25% darunavir AUC ↓ 44% darunavir Cmin ↓ 59% darunavir Cmax ↓ 36%
Darunavir binds primarily to plasma α1-acid glycoprotein.
Darunavir se primarno veže na α1-kiseli glikoprotein plazme.
Darunavir Krka with cobicistat or ritonavir has not been tested with all PIs (protease inhibitors) and must not be used with other HIV PIs.
Darunavir Krka s kobicistatom ili ritonavirom nije bio ispitan sa svim IP (inhibitori proteaze) i ne smije se uzimati s drugim IP HIVa.
The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg twice daily (see section 4.4).
Ukupni učinak pospješenja farmakokinetike ritonavirom bio je približno 14 puta veća sistemska izloženost darunaviru, kad se jednokratna doza od 600 mg darunavira dala peroralno u kombinaciji sa 100 mg ritonavira dvaput na dan (vidjeti dio 4.4).
375 milligram darunavir + 50 milligram ritonavir twice a day between 30 and 40 kilograms
375 miligrama darunavira + 50 miligrama ritonavira dvaput na dan između 30 i 40 kilograma
Darunavir co-administered with low dose ritonavir and etravirine 200 mg twice daily can be used without dose adjustments.
Darunavir istodobno primijenjen s niskom dozom ritonavira i etravirinom 200 mg dvaput na dan može se primijeniti bez prilagodbe doze.
ART-experienced paediatric patients from the age of 3 to < 6 years The pharmacokinetics, safety, tolerability and efficacy of darunavir/ritonavir twice daily in combination with other antiretroviral agents in 21 ART-experienced HIV-1 infected paediatric patients aged 3 to < 6 years and weighing 10 kg to < 20 kg was evaluated in an open-label, Phase II trial, ARIEL.
Pedijatrijski bolesnici prethodno liječeni ART-om u dobi od 3 do < 6 godina Farmakokinetika, sigurnost, podnošljivost i djelotovornost darunavira/ritonavira dvaput na dan u kombinaciji s drugim antiretrovirusnim lijekovima, procijenjene su u otvorenom ispitivanju ARIEL faze II, u 21 pedijatrijskog bolesnika prethodno liječenih ART-om inficiranih s HIV-1, u dobi od 3 do < 6 godina i težine 10 kg do < 20 kg.
Efavirenz in combination with darunavirmay result in sub-optimal darunavir Cmin.
Efavirenz u kombinaciji s darunavirom može rezultirati suboptimalnom vrijednošću Cmin darunavira.
Blood and lymphatic system disorders uncommon thrombocytopenia, neutropenia, anaemia, leukopenia rare increased eosinophil count
Poremećaji krvi i limfnog sustava manje često thrombocitopenija, neutropenija, anemija, leukopenija rijetko povišen broj eozinofila
Clinical monitoring is recommended when co-administering boosted darunavir with these antidepressants and a dose adjustment of the antidepressant may be needed.
Preporučuje se kliničko praćanje kada se ti antidepresivi primjenjuju istodobno s pojačanim darunavirom, a može biti potrebna prilagodba doze antidepresiva.
This dose must not exceed the recommended adult dose, which is 600 milligram Darunavir Krka together with 100 milligram of ritonavir two times per day or 800 milligram Darunavir Krka together with 100 milligram ritonavir once a day.
Ova doza ne smije prijeći preporučenu dozu za odrasle, koja je 600 miligrama lijeka Darunavir Krka zajedno sa 100 miligrama ritonavira dvaput na dan ili 800 miligrama lijeka Darunavir Krka zajedno sa 100 miligrama ritonavira jedanput na dan.
Voriconazole should not be combined with boosted darunavir unless an assessment of the benefit/risk ratio justifies the use of voriconazole.
Vorikonazol se ne smije kombinirati s pojačanim darunavirom, osim ako se procijeni da omjer koristi i rizika opravdava primjenu vorikonazola.
Darunavir Krka with ritonavir has not been tested with all PIs (protease inhibitors) and must not be used with other HIV PIs.
Darunavir Krka s ritonavirom nije bio ispitan sa svim IP (inhibitori proteaze) i ne smije se uzimati s drugim IP HIV-a.
Concomitant use of darunavir/ritonavir and darunavir/cobicistat with lopinavir/ritonavir, rifampicin and herbal products containing St John's wort, Hypericum perforatum, is contraindicated (see section 4.5).
Istodobna primjena darunavira/ritonavira i darunavira/kobicistata s lopinavirom/ritonavirom, rifampicinom i biljnim pripravcima koji sadrže gospinu travu, Hypericum perforatum, je kontraindicirana (vidjeti dio 4.5).
Based on theoretical considerations darunavir is expected to increase alfuzosin plasma concentrations.
Temeljeno na teorijskim postavkama očekuje se da će darunavir povećati koncentracije alfuzozina u plazmi.
Bosentan is expected to decrease plasma concentrations of darunavir and/or its pharmacoenhancer.
Za bosentan se očekuje da smanji koncentraciju darunavira i/ili njegovog farmakokinetičkog pojačivača. (CYP3A indukcija)
Darunavir and ritonavir are metabolised by CYP3A.
Darunavir i ritonavir se metaboliziraju putem enzima CYP3A.
If concomitant use of darunavir coadministered with low dose ritonavir with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended.
Ako je istodobna primjena darunavira primijenjenog istodobno s niskom dozom ritonavira indicirana sa sildenafilom, vardenafilom ili tadalafilom, tada su preporučene sljedeće doze: jednokratna doza sildenafila ne prelazi 25 mg u 48 sati, jednokratna doza vardenafila ne prelazi 2,5 mg u 72 sata ili jednokratna doza tadalafila ne prelazi 10 mg u 72 sata.
Darunavir may therefore have different recommendations for concomitant medications depending on whether the compound is boosted with ritonavir or cobicistat.
Stoga su moguće različite preporuke za uzimanje darunavira s istodobno primijenjenim lijekovima ovisno o tome je li pojačan s ritonavirom ili s kobicistatom.
Darunavir Krka might increase the risk of bleeding.
Darunavir Krka može povećati rizik krvarenja.
Rash occurred more commonly in treatment-experienced patients receiving regimens containing darunavir/ritonavir + raltegravir compared to patients receiving darunavir/ritonavir without raltegravir or raltegravir without darunavir (see section 4.8).
Osip se javio češće u bolesnika s iskustvom u liječenju po režimima koji sadrže darunavir/ritonavir + raltegravir u usporedbi s bolesnicima koji su liječeni darunavirom/ritonavirom bez raltegravira ili raltegravirom bez darunavira (vidjeti dio
Therefore, darunavir must only be used in combination with low dose ritonavir as a pharmacokinetic enhancer (see sections 4.4 and 5.2).
Stoga se darunavir mora primjenjivati samo u kombinaciji s niskom dozom ritonavira koji služi kao farmakokinetički pojačivač (vidjeti dijelove 4.4 i 5.2).
When used for birth control, alternative methods of nonhormonal contraception are recommended.
Za zaštitu od začeća, preporučuju se drugi oblici nehormonske kontracepcije. - etinilestradiol/drospirenon.
Skin and subcutaneous tissue disorders very common rash (including macular, maculopapular, papular, erythematous, pruritic rash, generalised rash, and allergic dermatitis)
Poremećaji kože i potkožnog tkiva vrlo često osip (uključujući makularni, makulopapularni, papularni, eritematozni, pruritički osip, generalizirani osip i alergijski dermatitis)
- The other ingredients are cellulose, microcrystalline; crospovidone, hydroxypropylcellulose; silica, colloidal anhydrous; silicified microcrystalline cellulose (cellulose, microcrystalline; silica, colloidal anhydrous) and magnesium stearate (E470b) in the tablet core and poly(vinyl alcohol), macrogol, titanium dioxide (E171), talc (E553b), yellow iron oxide (E172) - only for 400 mg film-coated tablets and red iron oxide (E172) in film coating.
- Drugi sastojci su mikrokristalična celuloza, krospovidon, hidroksipropilceluloza, koloidni bezvodni silicijev dioksid, silicificirana mikrokristalična celuloza (mikrokristalična celuloza, koloidni bezvodni silicijev dioksid) i magnezijev stearat (E470b) u jezgri tablete te poli(vinilni alkohol), makrogol, titanijev dioksid (E171), talk (E553b), žuti željezov oksid (E172)samo za 400 mg filmom obložene tablete i crveni željezov oksid (E172) u film ovojnici tablete.
400 mg once daily didanosine AUC ↓ 9% didanosine Cmin ND didanosine Cmax ↓ 16% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
400 mg jedanput na dan didanozin AUC ↓ 9% didanozin Cmin ND didanozin Cmax ↓ 16% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
6/l (see section 4.1) a regimen of 800 mg once daily with ritonavir 100 mg once daily taken with food may be used.
6/l (vidjeti dio 4.1) može se primijeniti režim doziranja od 800 mg jedanput na dan uz ritonavir od 100 mg jedanput na dan, s hranom.
450 milligram darunavir + 60 milligram ritonavir twice a day more than 40 kilograms*
450 miligrama darunavira + 60 miligrama ritonavira dvaput na dan više od 40 kilograma*
Darunavir must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.
Darunavir se uvijek mora primjenjivati peroralno s niskom dozom ritonavira kao farmakokinetičkim pojačivačem i u kombinaciji s drugim antiretrovirusnim lijekovima.
Concentrations of these medicinal products may be increased when coadministered with boosted darunavir resulting in the potential for increased adverse events usually associated with these agents.
Koncentracije tih lijekova mogu s povećati kada se primjenjuju istodobno s pojačanim darunavirom rezultirajući potencijalom za povećanje nuspojava obično povezanih s tim lijekovima.
Darunavir co-administered with low dose ritonavir should not be used in combination with these medicines.
Darunavir istodobno primijenjen s niskom dozom ritonavira ne smije se primjenjivati u kombinaciji s ovim lijekovima.
Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).
Darunavir Krka, primijenjen istodobno s niskom dozom ritonavira, indiciran je u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje bolesnika koji su inficirani virusom humane imunodeficijencije (HIV-1) (vidjeti dio 4.2).
Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.
Darunavir Krka, primijenjen istodobno s niskom dozom ritonavira, indiciran je u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje bolesnika koji su inficirani virusom humane imunodeficijencije (HIV-1).
400 mg film-coated tablets:
400 mg filmom obložene tablete:
See the Summary of Product Characteristics for Darunavir Krka 600 mg tablets.
Vidjeti sažetak opisa svojstava lijeka za Darunavir Krka 600 mg tablete.
Imputations according to the TLOVR algorithm d Based on normal approximation to the difference in % response Non-completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0
Na temelju normalne aproksimacije razlike u % odgovora Bolesnik koji nije završio ispitivanje zabilježen je kao neuspjeh: bolesnicima koji su prijevremeno prekinuli ispitivanje pripisana je promjena jednaka 0
Plasma concentrations of these medicinal products may be increased when co-administered with darunavir with low dose ritonavir, resulting in reduced serum cortisol concentrations.
Koncentracije ovih lijekova u plazmi mogu biti povišene kada se primjenjuju istodobno s darunavirom s niskom dozom ritonavira, dovodeći do sniženih koncentracija kortizola u serumu.
When darunavir is coadministered with a drospirenone-containing product, clinical monitoring is recommended due to the potential for hyperkalaemia.
Kada se darunavir istodobno primjenjuje s lijekovima koji sadrže drospirenon preporučuje se kliničko praćenje radi rizika od nastanka hiperkalemije.
It is not recommended to co-administer boosted darunavir with glecaprevir/pibrentasvir.
Ne preporučuje se istodobna primjena pojačanog darunavira s glekaprevirom/pibrentasvirom
Monitoring of renal function may be indicated when boosted darunavir is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Praćenje funkcije bubrega može biti indicirano kada se pojačan darunavir daje u kombinaciji s tenofovir dizoproksilom, posebno u bolesnika s podležećom sistemskom ili bubrežnom bolešću ili u bolesnika koji uzimaju nefrotoksične lijekove.
For patients with renal impairment the Summary of Product Characteristics for clarithromycin should be consulted for the recommended dose.
Za bolesnike s oštećenjem bubrega za preporučenu dozu mora se pročitati sažetak opisa svojstava lijeka za klaritromicin.
The use of boosted darunavir and these anticoagulants is not recommended.
Ne preporučuje se istodobna primjena pojačanog darunavira i ovih antikoagulansa.
No adjustment of methadone dosage is required when initiating coadministration with darunavir /ritonavir.
Prilagodba doziranja metadona nije potrebna kada se započinje istodobna primjena s darunavirom/ritonavirom.
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when coadministered with boosted darunavir.
Nužan je oprez, te ako je dostupno, preporučuje se praćenje terapijskih koncentracija za ove antiaritmike kada se primjenjuju istodobno s pojačanim darunavirom.
# in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
#u tablici ispod) provodilo se s nižom dozom darunavira od preporučene ili uz različit režim doziranja (vidjeti dio 4.2 Doziranje).
The exposure to total darunavir and ritonavir after intake of darunavir/ritonavir 600/100 mg twice daily and darunavir/ritonavir 800/100 mg once daily as part of an antiretroviral regimen was generally lower during pregnancy compared with postpartum.
Ukupna izloženost darunaviru i ritonaviru nakon primjene darunavira/ritonavira 600/100 mg dvaput na dan i darunavira/ritonavira 800/100 mg jedanput na dan kao dio antiretrovirusnog liječenja bila je općenito niža tijekom trudnoće u usporedbi s postpartalnim razdobljem.
darunavir/ritonavir N=80
Ishodi u 48. tjednu darunavir/ritonavir N=80
Phenobarbital and phenytoin are expected to decrease plasma concentrations of darunavir and its pharmacoenhancer.
Za fenobarbital i fenitoin se očekuje da smanje koncentracije darunavira i njegovog farmakokinetičkog pojačivača u plazmi. (indukcijom CYP450 enzima)
Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir (e.g. rifampicin, St John's wort, lopinavir).
Moglo bi se očekivati da lijekovi koji induciraju aktivnost CYP3A povećavaju klirens darunavira i ritonavira, što bi rezultiralo nižim koncentracijama darunavira i ritonavira u plazmi (npr. rifampicin, gospina trava, lopinavir).
Co-administration with herbal preparations containing St John's wort (Hypericum perforatum) (see section 4.5).
Istodobna primjena s biljnim pripravcima koji sadrže gospinu travu (Hypericum perforatum) (vidjeti dio 4.5).
CORTICOSTEROIDS
KORTIKOSTEROIDI
The evidence of efficacy of darunavir/ritonavir 800/100 mg once daily is based on the analyses of 192 week data from the randomised, controlled, open-label Phase III trial ARTEMIS in antiretroviral treatment-naïve HIV-1 infected patients comparing darunavir/ritonavir 800/100 mg once daily with lopinavir/ritonavir 800/200 mg per day (given as a twice-daily or as a once-daily regimen).
Djelotvornost darunavira od 800 mg jedanput na dan primijenjenog istodobno sa 100 mg ritonavira jedanput na dan u bolesnika prethodno neliječenih ART-om Dokaz djelotvornosti darunavira/ritonavira 800/100 mg jedanput na dan temelji se na analizi podataka dobivenih nakon 192 tjedna randomiziranog, kontroliranog, otvorenog ispitivanja faze III pod nazivom ARTEMIS, provedenog u bolesnika inficiranih virusom HIV-1, prethodno neliječenih ART-om, u kojem se uspoređivao darunavir/ritonavir 800/100 mg jedanput na dan s lopinavirom/ritonavirom 800/200 mg na dan (primijenjen u režimu dvaput na dan ili jedanput na dan).
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when coadministered with darunavir with low dose ritonavir.
Nužan je oprez, te ako je dostupno, preporučuje se praćenje terapijskih koncentracija za ove antiaritmike kada se primjenjuju istodobno s darunavirom s niskom dozom ritonavira.
Immune system disorders uncommon immune reconstitution inflammatory syndrome, (drug) hypersensitivity
Poremećaji imunološkog sustava manje često upalni sindrom imunološke rekonstitucije, preosjetljivost (na lijek)
In the morning, take one 600 milligram Darunavir Krka tablet together with 100 milligram ritonavir.
- Ujutro uzmite jednu tabletu lijeka Darunavir Krka od 600 miligrama zajedno sa 100 miligrama ritonavira.
Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are
Preporučeno je kliničko praćenje terapijskih učinaka i nuspojava
Concomitant administration of darunavir with low dose ritonavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Istodobna primjena darunavira s niskom dozom ritonavira i kvetiapina je kontraindicirana jer može povisiti toksičnost povezanu s kvetiapinom.
Lopinavir/ritonavir 533/133.3 mg twice daily lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38% darunavir Cmin ↓ 51% darunavir Cmax ↓ 21% lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% based upon non dose normalised values
Lopinavir/ritonavir 533/133,3 mg dvaput na dan lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38% darunavir Cmin ↓ 51% darunavir Cmax ↓ 21% lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% na temelju normaliziranih vrijednosti neovisnih o dozi
An increase of systemic exposure to darunavir was observed when darunavir co-administered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day).
Povišena sistemska izloženost darunaviru primijećena je kad je darunavir istodobno primjenjen sa 100 mg ritonavira i rifabutinom (150 mg jedanput svaki drugi dan).